Dan Steiber, RPh Specialty Pharmacy Times Editor-in-Chief

NASP maintains a strong focus on policies affecting the national, legislative, and regulatory landscape of specialty pharmacy year round.

The annual Asembia Specialty Pharmacy Summit is the largest annual conference in the United States focused on specialty the specialty space.

Market access and health care professionals must work to find the balance to provide solid treatment for cancer without burdening the system to a point of collapse.

The first of 2 showcase events in the specialty space brings thousands of stakeholders from pharmacies, manufacturers, and service providers.

Emerging oncology therapies, often made available to patients through specialty pharmacies, continue to be a key driver and focus of the business.

Regardless of the quality of services offered by a specialty pharmacy, the inability to connect those services to the physician, payer, pharma organization, and patient make it difficult to be successful.

If direct and indirect remuneration fees are to remain, the health care system must recognize that specialty pharmacies provide different services to patients.

CBI Channel Trends Trade and Specialty Data conference delves into the core topics in the supply chain for both traditional and specialty products.

Managing the complex environment of specialty products must be both strategic and tactical if you want to compete.

Specialty drugs can alter or eradicate diseases to increase both the quality of life and length of lifespan overall, but this progress and innovation comes with a price tag.

Specialty pharmacies need to determine their role with both existing and emerging therapies in the chain of value-based care.

Misinformation among consumers and the media regarding specialty pharmacies illustrates the importance of leveraging factual information to highlight specialty services for patients to raise the customer service bar even higher.

Payers prefer specialty pharmacies achieve third-party accreditation to confirm their commitment to quality.

Lines must be drawn among specialty pharmacies and manufacturers to ensure professional services do not exceed regulatory parameters.

Stakeholders must work together to combat media reports that incorrectly define specialty pharmacy by the cost of medications and not the services provided.

Several factors must be considered when selecting a supply-chain process.

PCSK9 inhibitors are about to make their debut, and specialty pharmacy is poised to play a key role in their management.

As oncology spending rises, insurers and manufacturers are looking to specialty pharmacy programs to maximize the effectiveness of cancer therapies.

The first biosimilar product in the United States has been approved, and the time is now for specialty pharmacists to become familiar with the use and regulation of these drugs.

As costly new specialty medications come to market, the role of the payer in controlling formularies is becoming increasingly apparent.

Knowledge of the specialty drug pipeline is essential in planning for your practice.

Specialty pharmacies face the complexities of managing relationships with patients, physicians, manufacturers, and payers.

When specialty pharmacists refine their skills and adapt their methods of providing services to patients, they are directing their own destinies and taking on a valuable role in the community.

Many specialty products require a limited access approach, and specialty pharmacists need to have knowledge of the distribution and supply chain structure.

Selection of the right distribution model is of key importance in the launch of a specialty product, where each of the stakeholders has specific needs and requirements that must be met.

The editor-in-chief of Specialty Pharmacy Times discusses the requirements of the new national pharmaceutical serialization and track and trace program.

The editor-in-chief of Specialty Pharmacy Times discusses the tactics used by pharmacy benefit managers and manufacturers to contain specialty therapy costs.

Specialty Pharmacy Times' editor-in-chief looks at the highlights of 2013 and considers the issues and trends poised to impact the future of specialty pharmacy.

Distribution models are the key drivers for new participants in the specialty space. Here's a thoughtful discussion on how to grow your business.

Welcome to our third annual special Oncology edition of Specialty Pharmacy Times! While new targeted oral medications are convenient and effective, they are also expensive and toxic, so the need for creating the greatest effectiveness from therapy is warranted. That's where specialty pharmacy comes in.